Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) remains a life-limiting condition with a major impact on the ability to lead a normal life. Although existing therapies may improve the outlook in some patients there remains a major unmet need to develop more effective therapies in this condition. There have be...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrell, Nicholas W., Archer, Stephen L., DeFelice, Albert, Evans, Steven, Fiszman, Monica, Martin, Thomas, Saulnier, Muriel, Rabinovitch, Marlene, Schermuly, Ralph, Stewart, Duncan, Truebel, Hubert, Walker, Gennyne, Stenmark, Kurt R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications 2013
Materias:
Pulmonary Hypertension–Academic Research Consortium: Anticipated Classes of New Medications and Molecular Targets
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641734/
https://www.ncbi.nlm.nih.gov/pubmed/23662201
http://dx.doi.org/10.4103/2045-8932.109940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641734/
https://www.ncbi.nlm.nih.gov/pubmed/23662201
http://dx.doi.org/10.4103/2045-8932.109940

Ejemplares similares